New research published in Cell has identified specific immune system abnormalities that distinguish long COVID patients from those who recovered fully. The findings, from a large Stanford University study, show persistent low-level viral antigen in gut tissue, altered cortisol production, and abnormal T-cell responses as consistent features of long COVID. These markers may explain the fatigue, cognitive impairment, and autonomic dysfunction that characterize the condition.
The identification of specific biological targets is enabling the development of directed treatment protocols for clinical testing. Several clinical trials testing antiviral treatments, low-dose naltrexone, and immune modulating therapies are underway with initial results expected later this year. The National Institutes of Health has designated long COVID research a priority area following sustained advocacy from patient communities numbering in the millions.
